IV IMMUNOGLOBULIN THERAPY OF GLOMERULONEPHRITIS
$0M01FY2002RRNIH
Weill Medical College Of Cornell Univ, New York NY
Investigators
Linked publications & trials
Paper 22292110Paper 20977343Paper 19906219Paper 19391080Paper 19017985Paper 18097152Paper 17316097Paper 17079285Paper 16763388Paper 16339698Paper 15526720Paper 15270860Paper 14962217Paper 14703595Paper 14625263Paper 14581545Paper 12654942Paper 12525204Paper 12468338Paper 12442030Paper 12393516Paper 12027270Paper 11967296Paper 11880731Paper 11821496Paper 11781358Paper 11605171Paper 11391167Paper 11335777Paper 11335753Paper 11170984Paper 11135346Paper 11085758Paper 11075607Paper 10912545Paper 10880061Paper 10807191Paper 10783035
Abstract
Membranoproliferative-glomerulonephritis (MPGN) is a kidney disease of unknown etiology which might cause over a variable period of time End State Renal Disease (ESRD). Recent studies have postulated that in MPGN patient there is a production of an autoantibody to the alternative pathway of complement which is called C3 nephritic factor (C3NeF) and it is thought to play a major role in development of MPGN. This study is designed to determine if IGIV can modulate the functional activity of C3NeF as it contains anti-idoitypic antibodies directed against C3NeF.
View original record on NIH RePORTER →